The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | Risk assessment & transplant decisions in multiple myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, comments on risk assessment in patients with newly diagnosed multiple myeloma (NDMM), highlighting its utility in transplant decisions. There are several ways of assessing a patient’s risk status at diagnosis, including clinical features, International Staging System (ISS) score, genetic profiling, and response to induction treatment. This score can help determine which patients should receive an autologous transplant. Whilst autologous hematopoietic stem cell transplantation (autoHSCT) has a beneficial role in some patients with NDMM, additional studies are required to determine the benefit of a second transplant. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
